Global Interleukin Inhibitors Market was valued at US $xx Mn in 2019 and is expected to reach $xx Mn by 2026, at a CAGR of 17.3%.
Global Interleukin Inhibitors Market Introduction
Interleukin inhibitors are immunosuppressive drugs that block the activity of interleukins. They are used to treat asthma, eczema, gout, arthritis, psoriasis, systemic sclerosis, ankylosing spondylitis, and other conditions. Interleukin inhibitors are monoclonal anti-interleukin antibodies that bind to particular interleukins and block their signaling function. In recent years, significant research efforts have resulted in a number of interleukin inhibitors in various stages of development, with some proving to be useful in the treatment of a variety of immune-mediated and inflammatory disorders.
Global Interleukin Inhibitors Market Dynamics
The increased global incidence of autoimmune diseases, rising geriatric population, and technical breakthroughs in the creation of new interleukin inhibitors are among the main drivers driving the market growth. A substantial paradigm change in the management of autoimmune disorders has also occurred. Because of their enhanced safety and effectiveness characteristics, targeted treatments are becoming more popular, which is likely to drive market growth.
According to a study from the Centers for Disease Control and Prevention (CDC), asthma affected 7.9% of the US population in 2018. Females and children aged 5 to 14 years are more likely to develop asthma. The prevalence rate was 7.5 % in children and 7.7 % in adults. Furthermore, the majority of patients find that interleukin-based treatments are highly helpful in controlling their asthma. Nucala, for example, is a humanised interleukin-5 (IL-5) antagonist monoclonal antibody used to treat severe eosinophilic asthma, according to GlaxoSmithKline Plc. As a result of the aforementioned reasons, the market is expected to grow throughout the forecast period.
In addition, new product launches are important growth drivers; for example, AbbVie, Inc. introduced Skyrizi (risankizumab-rzaa) for the treatment of plaque psoriasis in 2019. Sun Pharmaceutical Industries Inc. released Ilumya (tildrakizumab-asmn) for moderate-to-severe plaque psoriasis earlier this year. The upcoming releases of late-stage pipeline prospects are anticipated to boost demand. Product label extensions, such as Actemra for juvenile idiopathic arthritis and Dupixent for atopic dermatitis, are likely to boost uptake. Furthermore, promising results from ongoing clinical trials suggest that the market for IL inhibitors has a lot of margins to develop.
Global Interleukin Inhibitors Market Segment Analysis
Interleukin-23 inhibitors dominated the interleukin inhibitor market, thanks in large part to the bestselling medication Stelara. Tremfya was added to the section in 2017, Ilumya was added in 2018, and Skyrizi was added in 2019. Despite the fact that Stelara’s patent is about to expire in 2023, the IL-23 category is expected to develop rapidly due to new entries. Because of the strong sales of Cosentyx and Taltz, IL-17 is expected to be the fastest-growing segment throughout the forecast period. Taltz is anticipated to surpass USD 1 billion in sales in 2019, while Cosentyx became a blockbuster medication in its third year of release in 2017. Furthermore, the recent introduction of Siliq and the upcoming approval of bimekizumab are likely to have a beneficial influence on IL-17 growth.
Over the forecast period, the psoriasis segment is expected to have a significant market share.
Psoriasis is one of the most prevalent chronic skin disorders, and its prevalence is expected to rise as people become older. Increased disease prevalence, increased consumer awareness, and advantageous reimbursement policies are among the key reasons driving the psoriasis segment’s growth. Stelara, Cosentyx, Siliq, and Taltz are some of the FDA-approved interleukin inhibitors for psoriasis therapy. Psoriasis affects more than 125 million individuals worldwide, according to the International Federation of Psoriasis Associations 2020. Furthermore, persons with psoriasis have a higher risk of co-morbidities including diabetes and cardiovascular disease. The effect on mental health might be considered as well. Interleukin inhibitor demand is expected to rise throughout the projected period in order to prevent such psoriasis-related co-morbidities.
In addition, UCB announced in 2020 that the FDA has approved the Biologics License Application (BLA) for bimekizumab (UCB) for the treatment of moderate to severe plaque psoriasis in adults. As a result of the aforementioned factors, the market is expected to grow rapidly in the near future.
Global Interleukin Inhibitors Market
To know about the Research Methodology :- Request Free Sample Report
Global Interleukin Inhibitors Market Regional Insights
Global Interleukin Inhibitors Market 1
Over the forecast period, the North American region is expected to have a significant market share of xx%.
Due to the presence of key market players, growing research and development efforts in the creation of innovative products, aggressive government initiatives, and an increase in healthcare spending, the United States is anticipated to have a significant market share in the North American region. Major growth drivers include the existence of key pipeline medicines and label extensions of current medications for psoriatic arthritis, Crohn’s disease, and ulcerative colitis. According to the National Clinical Studies (NCT) Registry, there are more than 200 active clinical trials in the United States for interleukin inhibitors at various stages of development for various purposes as of December 2020. As a result of the aforementioned factors, the US market is expected to be one of the largest and to continue to grow in the future.
Throughout the forecast period, Asia Pacific is expected to grow at the fastest rate. Regional growth is likely to be aided by economic development, improvements in healthcare facilities, an increase in disposable income, and increased consumer awareness. Emerging economies like China, India, and South Korea are expected to grow rapidly.
Global Interleukin Inhibitors Market Report Scope:Inquire before buying
Global Interleukin Inhibitors Market 2
Global Interleukin Inhibitors Market, by Region
• North America
• Europe
• South America
• MEA
• Asia Pacific
Global Interleukin Inhibitors Market Key Players
• AbbVie
• AstraZeneca plc
• Eli Lily and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Investor AB (Swedish Orphan Biovitrum AB)
• Johnson & Johnsons
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd
• Bausch Health Companies Inc.
• Merck KGaA
• Sun Pharmaceutical Industries Ltd
• Genentech, Inc. (Roche)
• Valeant Pharmaceuticals, Inc.
